Prometic to Present New Data on how Plasminogen Reduces Acute Lung Injury at the American Thoracic Society's 2017 International Conference

  • Plasminogen administration shown to reduce acute lung injury ("ALI") in an acute pancreatitis model
  • ALI and its more severe form, acute respiratory distress syndrome ("ARDS") represent large unmet medical needs
  • ALI and ARDS affect approximately 190,000 patients / year in the US with a mortality rate of close to 40%

LAVAL, QC, May 8, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it will be presenting new data at the 2017 American Thoracic Society ("ATS") International Conference in Washington, D.C. showing the benefits of plasminogen administration in reducing lung injury in a gold standard animal model of ALI/ARDS associated with acute pancreatitis.

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are life-threatening conditions resulting in respiratory failure in the critically ill patient. ALI is the term used to describe the pulmonary response to a broad range of injuries occurring either directly to the lung or as a consequence of injury or inflammation at other sites of the body, such as acute pancreatitis, severe burns, trauma, or sepsis. ARDS represents the more severe subset of this condition. ALI and ARDS affect approximately 190,000 patients every year in the US, and are associated with a high mortality rate varying between 30% and 60%; both conditions representing significant unmet medical needs.

"ALI and ARDS are just two examples of acute critical care conditions we intend to pursue with our plasminogen product once it receives regulatory approval for congenital deficiency", stated Dr. John Moran, Prometic's Chief Medical Officer. "The remarkable results seen with plasminogen in this gold standard model for ALI/ARDS strongly suggests its potential to address these major unmet medical needs".    

Mr. Pierre Laurin, President and Chief Executive Officer of Prometic commented: "We have an exciting program at this year's ATS conference, not only these excellent results with plasminogen, but also showcasing new data with respect to PBI-4050 for IPF as well as PBI-4425 for scleroderma and for emphysema".

Oral presentation at the conference:

PBI-4050 Is Safe and Well Tolerated and Shows Evidence of Benefit in Idiopathic Pulmonary Fibrosis
Session: B14 - CLINICAL TRIALS ACROSS PULMONARY DISEASE
Date: Monday, May 22, 2017
Time: 9:15 AM-11:15 AM

Poster presentation at the conference:

Plasminogen Reduces Acute Lung Injury in an Acute Pancreatitis Model
(ID 10663)

D109-Understanding The Mechanisms Of Acute Lung Injury
Poster Discussion Session
Wednesday, May 24; 1:30 PM-3:30 PM

PBI-4425, a Novel First-in-Class Anti-Inflammatory/Anti-Fibrotic Compound, Reduces Pulmonary Emphysema and Cutaneous Hyperplasia in Tight-Skin (Fbn-1) Mouse (ID 11120)

C79-Advancing Understanding of Obstructive Lung Disease: Medications And Mechanisms Of Delivery
Thematic Poster Session
Tuesday, May 23; 9:15 AM-4:15 PM

PBI-4425, a Novel First-in-Class Anti-Inflammatory/Anti-Fibrotic Compound, Inhibits Collagen I and CTGF Production in Human Fibroblasts, and Reduces Lung Fibrosis in the Bleomycin-Induced Lung Fibrosis Model (ID 10405)

C75-Fibrosis: Current And Future Approaches
Thematic Poster Session
Tuesday, May 23; 9:15 AM-4:15 PM

PBI-4050 Reduces Expression of Fibrosis Biomarkers in the BioMAP SAEMyoF Primary Human Small Airway Epithelial Cells and Lung Myofibroblasts System (ID 11051)

D29-Unraveling The Extracellular Matrix
Poster Discussion Session
Wednesday, May 24; 9:15 AM-11:15 AM

Oral Treatment with PBI-4050 Reduces Acute Lung Injury in an Acute Pancreatitis Model (ID 10280)

D109-Understanding The Mechanisms Of Acute Lung Injury
Poster Discussion Session
Wednesday, May 24; 1:30 PM-3:30 PM

More about Acute Lung Injury and Acute Respiratory Distress Syndrome

Acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) are life-threatening complications causing respiratory insufficiency in the critically ill patient. ALI is the term used to describe the pulmonary response to a broad range of injuries occurring either directly to the lung or as a consequence of injury or inflammation at other sites of the body. ARDS represents the more severe end of the spectrum of this condition. The syndromes are associated with a high mortality rate varying between 30% and 60%.

More about Plasminogen

Plasminogen is a naturally occurring protein that is synthesized by the liver and circulates in the blood. Activated plasminogen, plasmin, is a fundamental component of the fibrinolytic system and is the main enzyme involved in the lysis of blood clots and clearance of extravasated fibrin. Plasminogen is therefore vital in wound healing, cell migration, tissue remodeling, angiogenesis and embryogenesis.

More about PBI-4050 & PBI-4425

PBI-4050 & PBI-4425 are orally active lead drug candidate targeting fibrosis.  PBI-4050 is entering phase 2/3 clinical trials after demonstrating efficacy and excellent safety profiles in three phase 2 open label clinical trials. PBI-4425 is scheduled to enter clinical trials in Q1 2018.  Fibrosis is a very complex process by which continuing inflammation causes vital organs to lose their function as normal tissue is replaced by fibrotic scar tissue. The proof of concept data generated to date confirms our lead drug candidates' anti-fibrotic activity in several key organs including the kidneys, the heart, the lungs and the liver. PBI-4050 has on-going clinical in patients with metabolic syndrome and Type 2 diabetes, cystic fibrosis and related diabetes and Alstrom Syndrome.  The plan Phase 2/3 clinical trials scheduled to commence this year target patients with idiopathic pulmonary fibrosis (IPF) and chronic kidney disease ("CKD").  Twenty-six million subjects in the U.S. alone are believed to suffer from CKD. Subjects with severe CKD stages (3 and 4) suffer from a progressive loss of their renal function leading to end-stage renal disease and the need for dialysis or kidney transplant. Cardiovascular complications are the most common cause of death in dialysis patients.

About Prometic Life Sciences Inc.       

Prometic Life Sciences Inc. (www.prometic.com) is a long established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. Prometic offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. Prometic is also active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune diseases/inflammation as well as certain nephropathies. Headquartered in Laval (Canada), Prometic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and commercial activities in the U.S., Canada, Europe, Russia, Asia and Australia.

Forward Looking Statements

This press release contains forward-looking statements about Prometic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Prometic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Prometic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Prometic's Annual Information Form for the year ended December 31, 2016, under the heading "Risk and Uncertainties related to Prometic's business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.

                                                           

SOURCE ProMetic Life Sciences Inc.

For further information: Pierre Laurin, President and CEO, Prometic Life Sciences Inc., p.laurin@prometic.com, +1.450.781.0115; Frédéric Dumais, Senior Director, Communications and Investor Relations, Prometic Life Sciences Inc., f.dumais@prometic.com, +1.450.781.0115

RELATED LINKS
http://www.prometic.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890